Albert Bourla, AP

Covid-19 roundup: CanSi­no eyes more over­seas PhI­II sites as Cana­da tri­al re­port­ed­ly stalls; In­di­an drug­mak­er surges on 30-per­son da­ta

Hav­ing lever­aged con­nec­tions in Cana­da for a planned Phase III tri­al of its Covid-19 vac­cine, CanSi­no is ven­tur­ing out to a few more oth­ers as it plots a glob­al late-stage pro­gram.

“We are con­tact­ing Rus­sia, Brazil, Chile and Sau­di Ara­bia, and it’s still in dis­cus­sion,” Dongxu Qiu, ex­ec­u­tive di­rec­tor and co-founder of CanSi­no, said at a con­fer­ence in Suzhou, Chi­na, per Reuters.

The tri­al is like­ly to start “pret­ty soon,” he added, with plans to re­cruit 40,000 par­tic­i­pants to­tal.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.